ArticleInternational journal of surgery (London, England)2026
Efficacy and safety of aerosol inhalation of recombinant human interferon-α2b injection in children hospitalized with human adenovirus pneumonia: a prospective, multicenter, randomized, controlled trial in China.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman adenovirus (HAdV) pneumonia represents one of the gravest threats to child health worldwide. However, effectively and safely antiviral strategies for HAdV infections remain limited. In this study, we aimed to comprehensively investigate the efficacy and safety of aerosol inhalation of recombinant human interferon-α2b (IFN-α2b) injection in children hospitalized with HAdV pneumonia.
methodsThis randomized controlled trial recruited children aged ≤5 years hospitalized for HAdV pneumonia from nine hospitals in China. Subjects were randomized 1:1 to receive either aerosol inhalation of IFN-α2b (200 000 IU/kg) plus routine supportive treatment or aerosolized normal saline plus supportive therapy, with a 7-day treatment period. Primary outcome indexes were viral DNA negative conversion rate and overall effective rate, while the secondary indexes included disappearance time of various symptoms, overall symptom improvement rate (OSIR), and levels of inflammatory indicators (TNF-α, IL-6, CRP, and LDH). Noteworthily, besides common clinical and laboratory indexes, two crucial effector proteins [2',5'-oligoadenylate synthetase (OAS), β2 microglobulin (β2M)] of IFN-mediated antiviral responses were assayed using the ELISA method. Additionally, safety assessment parameters consisted of vital signs, biochemical indicators of liver and kidney function (ALT, AST, urea, creatinine), and incidence of adverse events.
resultsA total of 140 eligible subjects were enrolled, including 70 in the IFN-α2b group and 70 in the control group. After 7-day therapy, compared to control group, the IFN-α2b group demonstrated significant superiority in therapeutic effects, including shorter disappearance time of various clinical symptoms, greater OSIR (0.84 ± 0.14 vs. 0.72 ± 0.11, P = 0.039), lower levels of inflammatory indicators (TNF-α, IL-6, CRP), and higher rates of viral DNA negative conversion [71.4 vs. 52.9%, RR (95% CI) = 1.35 (1.04-1.76), P = 0.023] and overall clinical effective [97.1 vs. 85.7%, RR (95% CI) = 1.13 (1.02-1.26), P = 0.016] with a more prominent clinical cure proportion [70.0 vs. 48.6%, RR (95% CI) = 1.44 (1.08-1.92), P = 0.010]. Meanwhile, higher serum OAS [85.1 (78.3-91.5) vs. 67.4 (63.5-71.0) U/mL, P = 0.003] and β2M [5.3 (4.8-6.5) vs. 3.8 (3.4-4.6) mg/L, P < 0.001] levels were confirmed in the IFN-α2b group than the control group after 7-day intervention. In terms of safety, there were no remarkable between-group differences regarding vital signs, liver/kidney function indexes, and incidence of adverse events.
conclusionAerosol inhalation of recombinant human IFN-α2b injection is safe and effective for treating pediatric HAdV pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.